Addressing the Global Challenges of COPD and Asthma: A Shared Vision From the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA)
Global Challenges of COPD and Asthma
GOLD and GINA Shared Vision to Improve Outcomes
GOLD and GINA have a shared purpose in working to improve outcomes for patients with chronic obstructive pulmonary disease (COPD) and asthma.
This joint statement is dedicated to Professor Eric Bateman, an inaugural member of the GINA Science Committee and member of the GINA Board, and to Professor Robert Rodriguez-Roisin, a founder and chair of the GOLD board of directors, both recently deceased.
Both made invaluable contributions to asthma and COPD research and took a global perspective on the challenges of diagnosis and management.
It was partly Professor Bateman’s idea that GOLD and GINA should produce a joint statement addressing the similar challenges faced in the prevention, early and accurate diagnosis and management of both COPD and asthma, emphasising the determination of both organisations to work together to address these issues.
Global Burden of COPD and Asthma
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Global Initiative for Asthma (GINA) have produced strategy reports and recommendations about diagnosis and management for these two commonest lung diseases every year for the last 25 years.
Approximately 650 million children and adults have Chronic Obstructive Pulmonary Disease (COPD) or asthma, and their prevalence is forecast to more than double by 2050.
In 2021 over 4 million people died from these diseases and COPD currently is the third commonest cause of death worldwide.
Asthma is the most common chronic disease in children under 15 and 1 in 3 children with asthma miss days from school.
The health and economic costs caused by COPD and asthma are high and rising.
Inequalities in Diagnosis and Treatment Worldwide
From a global perspective, non-communicable diseases (NCDs) have, for many years, been overshadowed by infectious (communicable) diseases.
In low and middle-income countries (LMIC) the growing prevalence of asthma and mortality rates globally remain unacceptably high, with 96% of asthma deaths occurring in these countries.
The morbidity and mortality caused by COPD in both high-income countries (HIC) and LMIC remain largely unrecognised.
Unlike other NCDs such as ischaemic heart disease and diabetes, asthma and COPD have not been prioritised by policy makers, resulting in inadequate access to diagnostic tools and treatments.
Commitment to Improve Access to Diagnosis and Treatment
GOLD and GINA are committed to addressing the global diagnostic and management challenges of asthma and COPD, particularly overcoming the shared problem of limited access to diagnosis and effective and affordable inhaled therapies.
Authors
David M. G. Halpin, Refiloe Masekela, Claus F. Vogelmeier, Obianuju B. Ozoh, Alvaro A. Cruz, Helen K. Reddel, Arzu Yorgancıoğlu, Alvar Agusti
Read more details at
Fecha de publicación
First published: 01 February 2026
Categorías asociadas al artículo
Noticias relacionadas
Iniciativa ‘Sense Límits’ de SOCAP y Chiesi: Concienciación y Apoyo a Enfermedades Respiratorias como EPOC y Asma
La Societat Catalana de Pneumologia (SOCAP) y Chiesi han lanzado la iniciativa ‘Sense Límits’ para concienciar sobre las enfermedades respiratorias, con actividades divulgativas y solidarias como espirometrías, pedaleos solidarios y marchas nórdicas, promoviendo la investigación científica y el cuidado de la salud respiratoria.
¿Cómo podría la inteligencia artificial mejorar la experiencia del paciente en el ámbito ambulatorio? Reflexiones del grupo JANUS
Explora cómo la IA puede mejorar en el ámbito ambulatorio del paciente, desde la toma de decisiones clínicas hasta el empoderamiento del paciente. Reflexiones del grupo JANUS basadas en su experiencia como sanitarios y pacientes.
Change is in the air: key questions on the ‘Treatable Traits’ model for chronic airway diseases in primary care
Explore Treatable Traits model for chronic airway diseases like asthma and COPD in primary care. Learn about seven key traits — airflow obstruction, eosinophilic inflammation, adherence, inhaler technique, smoking, low BMI/obesity and anxiety and depression — that guide personalized care.
Las enfermedades respiratorias centrarán «La Marató 2024»
La Fundación La Marató de TV3 organiza el evento anual «La Marató 2024», que busca recaudar fondos para la investigación científica de enfermedades que no tienen cura
1ª Edición de RESPrimaria. ABC de la Patología Respiratoria en Atención Primaria
El 08/05/2024 se celebrará la 1ª Edición de RESPrimaria, jornada dedicada a la actualización de la neumología en Atención Primaria. Posibilidad de asistencia presencial y online.
Tackling the global burden of lung disease through prevention and early diagnosis
The Global Burden of Disease Study 2017 identified that a country’s sociodemographic index was a key factor affecting mortality and loss of health from respiratory diseases.
Imágenes: Una obtenida del paper y otra generada con ChatGPT